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A simple process of in vitro folding has been developed for the preparation of hirudin dimer. A variant of recombinant hirudin with Asp33 replaced 
by Cys was expressed in yeast and isolated by HPLC. Crude Cys”-hirudin contains heterogeneous products that are made of one species of primary 
sequence. They were together educed/denatured, and allowed to re-fold in the sodium bicarbonate buffer @H 8.3) alone. Active, homogeneous 
Cys33-hirudin monomer folded spontaneously with a first order rate constant of0.05 f 0.01 mm-‘, followed by the oxidation of two Cys3’ to produce 
the pure dimer. The folding yield was 90%. On an equal weight basis, both Cys33-hirudin monomer and the dimer exhibit thrombin inhibitory activity 
comparable to that of wild-type hirudin. Due to the presence of an extra cysteine, the folding of active hirudin monomer (formation of three native 
disulfides) was accelerated by at least 1Zfold. 
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1. INTRODUCTION 
Hirudin (containing 65 amino acids and three disul- 
fide bonds) is a thrombin-specific inhibitor originally 
isolated from leech Hirudo medicinalis [l]. Recombinant 
hirudin is now produced in large quantities from yeast 
[2] and is under development as an antithrombotic drug 
[3]. Recombinant hirudin has a relatively short half-life 
and is rapidly excreted from the human body [4]. In 
order to evaluate the application of longer active hi- 
rudins, higher molecular weight forms, such as a hi- 
rudin dimer, have been synthesized. Such modified 
hirudins can be expressed and fold naturally if proper 
inter-disulfide bonds are created to link the monomers. 
Hirudin contains two functional domains which bind to 
independent sites of a-thrombin [5-71. A compact 
N-terminal core domain binds to the catalytic site of 
thrombin [8] and a disordered C-terminal tail which is 
complementary to the exosite (fibrinogen recognition 
site) of the enzyme [9,10]. Linking two monomers 
through the C-terminal region is not desirable as nearly 
every amino acid residue inside this domain is required 
for full potency [8,9]. Within the core domain, however, 
there is a flexible loop (residues 31-36) [11,12] which is 
located on the surface and is distant from the thrombin 
binding site. Amino acid sequence data have revealed 
that mutations of hirudin variants [13] within this loop 
do not significantly alter the activity of hirudin. Most 
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importantly, dimer linkage via this loop would proba- 
bly impose only a minimum interference upon the bind- 
ing of the dimer to two separate thrombins. This report 
describes the in vitro folding and dimerization of yeast- 
expressed Cys33-hirudin, a mutant of desulfato hirudin 
variant 1 (HV 1) [14]. 
2. EXPERIMENTAL 
2.1. Isolation of crude Cy?3-hirudin 
The expression in yeast (Saccharomyces cerevisiae) of Cyss3-hirudin, 
a mutant of the recombinant HV 1, with cysteine replacing aspartic 
acid at amino acid position 33, was achieved by changing the nucleo- 
tide sequence coding for hirudin by an overlap PCR reaction. GAC 
was replaced by TGT in the coding sequence of mutant hirudin. The 
amplified DNA fragment was cloned in the 2-micron based, high copy 
number yeast expression vector, pDP 34, as described in [2]. Cells of 
the matured culture broth were removed by centrifugation and pro- 
teins showing anti-thrombin activity (see below) were removed from 
the supematant by adsorption on XAD-7 resin. A mixture of active 
proteins was eluted with ammonium acetate buffer (0.2 M, pH 8.5) 
and applied to a Q-Sepharose fast-flow ion-exchange column. This 
column was eluted with ammonium formate buffer (25 mM), using a 
gradient elution from 0% A (buffer adjusted to pH 5.0 with formic 
acid) to 85% B (buffer adjusted to pH 3.0 with formic acid and 
containing 0.5 M sodium chloride) within 50 min. Fractions showing 
anti-thrombin activity were pooled and lyophilized to dryness (crude 
Cys”-hirudin). 
2.2. Folding of reducedldenatured Cys”-hirudin 
The crude Cys33-hirudin (4 mg) was reduced for 2 h at 23°C in 
0.75 ml of Tris-HCl buffer (0.5 M, pH 8.4) containing 5 M GdmCl and 
0.1 M dithiothreitol. The sample was passed through a PD-10 column 
(Pharmacia) equilibrated in 50 mM sodium bicarbonate buffer, pH 
8.3. The reduced/denatured sample was collected in 1.2 ml and was 
immediately diluted with the same sodium bicarbonate buffer to a 
final concentration of 1 mgAnl(l40 ,uM). The folding was carried out 
at 23°C and folding intermediates were trapped in a time-course 
manner by acidifying aliquots of folding sample with 2 ~01s. of 4% 
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trifluoroacetic acid. Wild-type hirudin (HV 1) was reduced/denatured 
and allowed to refold under identical conditions both in the absence 
and presence of /I-mercaptoethanol(l40 pM). 
2.3. HPLC characterization of the folding intermediates 
Acid-trapped folding intermediates were directly analysed by HPLC 
using the conditions described in the legend to Fig. 1. 
2.4. Characterization of the Cy?3-hirudin monomer and dimer 
Amino acid composition was determined by the dimethylami- 
noazobenzene sulfonyl (dansyl) chloride method [15], which allows 
direct quantitation of the disulfide content. Amino acid sequence was 
analysed by an Applied Biosystem Inc. 470A protein sequencer. The 
antithrombin activity of hirudin derivatives was assessed by their 
ability to inhibit a-thrombin from digesting Chromozym TH 
(Boehringer Mannheim), using the described protocol [16,171. Molec- 
ular weight of hirudin was determined by the laser desorption ioniza- 
tion mass spectrometry using a home-built instrument [18]. 
3. RESULTS AND DISCUSSION 
3.1. In vitro folding of the Cyd3-Cy$3-hirudin dimer 
Crude Cys33-hirudin was shown to be heterogeneous 
by HPLC. At least 7-8 species were observed (see inset 
in Fig. 1, top panel). However, analysis by peptide map- 
ping, sequencing and amino acid composition revealed 
that all these products are made of one species of pri- 
mary sequence. The crude Cys33-hirudin was reduced, 
carboxymethylated and digested by lysyl endopeptidase 
and V8 protease, its peptide mapping differs from that 
of wild-type hirudin by only one peptide, which was 
isolated and found to contain the sequence, Cys-Gln- 
CmCys-Val-Thr-Gly-Glu (residues 33-39). The hetero- 
geneity of the crude product thus must arise from 
improper folding after biosynthesis and secretion or 
sample destruction during purification. 
In order to obtain a pure species of folded CYSTS- 
hirudin, we have therefore performed this folding ex- 
periment. The process and results turned out to be 
surprisingly straightforward. Correct folding of re- 
duced/denatured Cys33-hirudin took place spontane- 
ously in alkaline buffer alone. Active Cys33-hirudin 
monomer formed first (Fig. 1, top panel) with a first 
order rate constant of 0.05 + 0.01 min-’ under the ex- 
perimental conditions described. Oxidation of CYSTS be- 
tween two active Cys33-hirudin monomers subsequently 
occurred and the cystine-linked dimer was generated. 
The folding was highly efficient with a yield of > 85 
90%. 
The Cys33-Cys33-hirudin dimer contains no free cyste- 
ine, as confirmed by amino acid analysis, and has an 
anticipated molecular mass of 13,9 16, as determined by 
laser desorption mass spectrometry. Both the CYSTS 
monomer and the dimer are highly active anti-coagu- 
lants and their potencies of thrombin inhibition are 
nearly indistinguishable (+ 3%). At a concentration of 
1 nM of hirudin and 1.5 nM of a-thrombin, the dimer 
exhibits, on an equal weight basis, 82-86% of the inhib- 
itory activity of wild-type hirudin. This suggests that 
one hirudin dimer binds to two molecules of a-throm- 
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Fig. 1. The process of folding of reduced/denatured hirudins. Cy$‘- 
hirudin in the buffer alone (top panel). Wild-type hirudin in the buffer 
containing 140 PM of B-mercaptoethanol (middle panel). Wild-type 
hirudin in the buffer alone (bottom panel). The buffer was 50 mM 
NaHCO, @H 8.3). The folding intermediates were trapped by acid in 
a time-course manner and analysed by HPLC using the following 
conditions. Column was Vydac C,, for peptides and proteins, 5 mm; 
solvent A was water containing 0.1% trifluoroacetic acid; solvent B 
was acetonitrile/water (9: 1, v/v) containing 0.1% trifluoroacetic acid. 
The gradient was 24-43% solvent B linear in 20 min; peptides were 
detected at 214 nm. Reduced/denatured (R) Cy?‘-hirudin and wild- 
type hirudin were eluted at 17.7 min and 18.8 min, respectively. ‘N’ 
is native wild-type hirudin (14.1 mm). ‘NM’ is active Cys”-hirudin 
monomer (13.5 min). ‘ND’ is Cys33-hirudin diier. In the absence of 
/I-mercaptoethanol, about 60% of the wild-type hirudin was trapped 
as scrambled 3-disutide species (see the 24h sample of bottom panel). 
Inset, crude Cys”-hirudin analysed by the same HPLC conditions. 
bin, which is not unexpected since the thrombin binding 
sites of hirudin are apparently not impaired as a result 
of dimerization (Fig. 2). 
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Fig. 2. Proposed structure of the Cys”Cys33-linked hirudin dimer. 
Hirudin contains a compact N-terminal domain (residues l-49) and 
a disordered C-terminal tail (residues S&65). The a-thrombin binding 
site of the N-terminal domain is opposite to the Cys”. The three native 
disultides within the monomer are Cy~~-Cys’~, Cy&Cysz8 and Cysz2- 
C)JP. 
3.2. The dimer and monomer are inter-convertible 
Unlike the three intra-disulfide bridges of hirudin, the 
Cy~~~-Cys~~ of the dimer is not stabilized by non-cova- 
lent interactions. It may therefore be possible to selec- 
tively cleave Cys33-Cys33 under mild reducing condi- 
tions without disrupting the three disulfides located 
within the active core domain. Experiments were car- 
ried out in order to find out an optimum condition that 
would allow quantitative conversion of the dimer to the 
monomer. This can be achieved by using 0.5-2.5 mM 
of /3-mercaptoethanol at room temperature (Fig. 3). At 
higher concentration of B-mercaptoethanol, the mono- 
mer rapidly disintegrates as a consequence of the reduc- 
tion of Cys6-Cysi4, Cy~‘~-Cys** and Cys**-Cy~~~. 
3.3. The folding mechanism of Cy?3-hirudin 
The folding intermediates of Cys33-hirudin were 
trapped by acidification and analysed by HPLC (Fig. 
1, top panel). The results are compared to those ob- 
tained from the folding of wild-type hirudin carried out 
both in the absence and presence of /?-mercaptoethanol 
(140 PM) (Fig. 1, middle and bottom panel). 
The folding pathway of hirudin has been recently 
shown to undergo a two-stage process of packing/con- 
solidation [19]. The course of packing was characterized 
as unfolded hirudin flowing sequentially and irreversi- 
bly through [equilibrated 1-disulfide isomers]-, 
[equilibrated 2-disulfide isomers]+[equilibrated 3-disul- 
fide (scrambled) isomers]. The mechanism of consol- 
idation involved reorganization and refinement of the 
scrambled species to attain the active structure. The 
efficiency of packing and consolidation, in our case, can 
be selectively regulated and conditions can be chosen to 
allow the completion of hirudin folding within 10 min 
or up to 10 h. The rate of packing is primarily enhanced 
by the oxidized glutathione, whereas the process of con- 
solidation requires free thiols (reduced glutathione or 
/&mercaptoethanol) as catalyst. In the presence of oxi- 
dized glutathione (2-10 mM) alone, the flow of packing 
completes within 2 min and consolidation become the 
major rate limiting step. As a consequence, scrambled 
hirudins become the only detectable folding intermedi- 
ates under these conditions. In the absence of both oxi- 
dized glutathione and supplementing free thiols, about 
60% (this number is dependent upon the concentration 
of protein employed for folding) of the starting material 
was trapped as scrambled 3-disulfide species which were 
unable to convert to the native hirudin (Fig. 1, bottom 
panel). This problem could be overcome by including 
catalytic amounts of /l-mercaptoethanol (or other free 
thiols such as reduced glutathione) in the folding sample 
(Fig. 1, middle panel). 
Based on the HPLC patterns, we conclude that CYSTS- 
hirudin most likely folds via similar mechanisms. Due 
to the presence of an extra cysteine (CYSTS), active CYSTS- 
hirudin monomer formed quantitatively without addi- 
tional thiol reagents. It is nonetheless interesting to ob- 
serve (top and middle panels of Fig. 1) that the folding 
of active Cys33-hirudin monomer is at least la-fold more 
efficient than that of wild-type hirudin in the presence 
of 140 PM p-mercaptoethanol (concentration identical 
to that of the extra CYSTS). These results suggest hat 
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Fig. 3. Coversion of Cys33-hirudin dimer to the monomer under mild 
reducing conditions. The dimer was dissolved in the folding buffer 
containing 0.5 mM (m), 2.5 mM (& or 10 mM (0) of/I-mercaptoetha- 
nol. Final concentration of the dimer was 7 ,uM. Reduction was car- 
ried out at 23°C. Partially reduced samples were trapped by acid in 
a time-course manner and directly analysed by HPLC using the same 
conditions described in Fig. 1. Chromatograms of samples reduced by 
0.5 mM of j?-mercaptoethanol are also presented. 
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CYSTS must provide a highly localized concentration of 
thiols which facilitate the disulfide equilibrium (shuf- 
fling) to reach the active structure. Thus, introducing an 
extra cysteine should, in principle, enhance the effi- 
ciency of the folding of cysteine-containing proteins. 
However, whether or not the introduced cysteine will 
eventually engage in the dimerization may well depend 
upon its position in the native structure of the protein. 
For instance, we speculate that if the cysteine substitu- 
tion of hirudin was located within the core domain (e.g. 
Serlg to Cys) instead of the surface loop (CYSTS), the 
efficiency of hirudin folding might be enhanced in the 
same manner, but the formation of the dimer should not 
be expected. Similar results of enhancement were ob- 
served recently by Weissman and Kim [20]. BPTI deriv- 
atives, attached by the Pro region or an extended 
C-terminal sequence which contain one extra cysteine, 
refold more efficiently than BPTI itself. These data 
together point out an unique route of influencing the 
efficiency of folding of disulfide containing proteins, as 
well as a simple way of creating disulfide-linked protein 
dimers. 
In conclusion, an efficient method for the large-scale 
production of hirudin dimer is described. It remains to 
be seen through pharmacokinetical and clinical analysis 
whether the hirudin dimer will have the advantage of an 
increased half-life. 
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